Connaughton Bernadette 4
4 · HALOZYME THERAPEUTICS, INC. · Filed May 2, 2025
Insider Transaction Report
Form 4
Connaughton Bernadette
Director
Transactions
- Award
Common Stock
2025-05-01+4,165→ 50,952 total - Award
Option to Purchase Common Stock
2025-05-01+5,750→ 5,750 totalExercise: $60.03Exp: 2035-05-01→ Common Stock (5,750 underlying)
Footnotes (2)
- [F1]Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.
- [F2]Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.